Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Recommendation of “Buy” by Analysts

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) have been given an average rating of “Buy” by the five research firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have covered the stock in the last year is $9.12.

Several research firms have recently weighed in on AUTL. Wells Fargo & Company decreased their price target on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, July 21st.

Autolus Therapeutics Price Performance

AUTL stock opened at $1.75 on Friday. Autolus Therapeutics has a 1-year low of $1.1050 and a 1-year high of $5.00. The business has a fifty day moving average price of $2.27 and a 200-day moving average price of $1.88. The stock has a market capitalization of $465.75 million, a P/E ratio of -2.08 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.06. The business had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $12.92 million. As a group, analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

Several large investors have recently modified their holdings of AUTL. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics in the fourth quarter worth $26,000. Barclays PLC grew its holdings in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company’s stock worth $28,000 after acquiring an additional 10,866 shares during the period. Marex Group plc bought a new stake in shares of Autolus Therapeutics in the second quarter worth $28,000. R Squared Ltd bought a new stake in shares of Autolus Therapeutics in the second quarter worth $50,000. Finally, Invesco Ltd. grew its holdings in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after acquiring an additional 11,381 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.